Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Soligenixsoligenix.com · Low evidenceSoligenix is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with unmet medical needs. Its Specialized BioTherapeutics pipeline includes HyBryte for Cutaneous T-Cell Lymphoma, SGX302 for mild-to-moderate plaque psoriasis, SGX942 for oral mucositis, and SGX945 for aphthous ulcers in Behçet’s Disease, spanning preclinical to Phase 3 and NDA review. The company also runs Public Health Solutions programs funded by the U.S. government, including RiVax to prevent ricin poisoning and ThermoVax thermostable vaccines for global use.
Parse Score